You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華東醫藥(000963.SZ):子公司英國Sinclair與KiOmed簽署獨家許可協議 引入創新型殼聚糖醫美產品
格隆匯 10-08 09:13

格隆匯10月8日丨華東醫藥(000963.SZ)公佈,2021年9月30日,公司英國全資子公司Sinclair Pharma Limited(簡稱“Sinclair”)與比利時KiOmed Pharma SA(簡稱“KiOmed”)簽署產品獨家許可協議。

Sinclair獲得KiOmed 4款在研的全球創新型KiOmedine®殼聚糖醫美產品以及後續開發的全部殼聚糖相關產品於除美國以外的全球其他區域在皮膚醫美領域的獨家許可,包括利用KiOmed相關知識產權進行研發、生產及商業化權益。

Sinclair將向KiOmed支付首付款400萬歐元,以及最高不超過1000萬歐元的研發註冊里程碑付款,和約定比例的淨銷售額提成費。

該次交易主要涉及KiOmed 4款在研的全球創新型KiOmedine®殼聚糖醫美產品,包括1款皮膚動能素(skinbooster)產品和3款填充劑產品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account